glp 1 crohn's disease The Potential for GLP-1s in the Treatment of GI and Hepatology News -

Loss of tumor suppressor Igfbp4 drives epigenetic reprogramming in hepatic carcinogenesis

We've found that empowering researchers with knowledge on proper handling and storage is just as critical

Antlanger, M

Trasatti C, Spears R, Gutmann JL, Opperman LA

specifically examined patients with MASLD cirrhosis and type 2 diabetes, finding that GLP-1 receptor agonist initiation was linked to reduced risk of unfavorable liver outcomes including hepatic decompensation events and mortality from any cause (aHR: 0.78, 95%CI: 0.68-0.90) relative to non-users, suggesting potential benefits even in advanced liver disease populations [58]

Many insurance plans place Wegovy in tier 2 or tier 3